{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:41:08Z","timestamp":1791042068158,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08173-0","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:14:45Z","timestamp":1780665285000},"page":"4287-4295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness and safety of apremilast in psoriatic arthritis: results from the multicenter Italian MAPSI II study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7551-4735","authenticated-orcid":false,"given":"Carlotta","family":"Schenone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Tramontano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Pendolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Faggioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"De Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Pirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Delle Sedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Camellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerolamo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"2","key":"8173_CR1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12325-021-02016-x","volume":"39","author":"K de Vlam","year":"2022","unstructured":"de Vlam K et al (2022) Real-world efficacy and safety of apremilast in Belgian patients with psoriatic arthritis: results from the prospective observational APOLO study. Adv Ther 39(2):1055\u20131067. https:\/\/doi.org\/10.1007\/s12325-021-02016-x","journal-title":"Adv Ther"},{"issue":"4","key":"8173_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jbspin.2018.01.011","volume":"85","author":"T Reygaerts","year":"2018","unstructured":"Reygaerts T, Mitrovic S, Fautrel B, Gossec L (2018) Effect of biologics on fatigue in psoriatic arthritis: a systematic literature review with meta-analysis. Joint Bone Spine 85(4):405\u2013410. https:\/\/doi.org\/10.1016\/j.jbspin.2018.01.011","journal-title":"Joint Bone Spine"},{"key":"8173_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534","author":"JA Walsh","year":"2023","unstructured":"Walsh JA et al (2023) Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105534","journal-title":"Joint Bone Spine"},{"key":"8173_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1484988","author":"T Serban","year":"2024","unstructured":"Serban T et al (2024) Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study. Front Med. https:\/\/doi.org\/10.3389\/fmed.2024.1484988","journal-title":"Front Med"},{"key":"8173_CR5","unstructured":"Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG (2018) Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. J Drugs Dermatol. Aug 1;17(8):835-840.."},{"key":"8173_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W (2018) Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.01048","journal-title":"Front Pharmacol"},{"issue":"6","key":"8173_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3899\/jrheum.211331","volume":"49","author":"LC Coates","year":"2022","unstructured":"Coates LC, Corp N, van der Windt DA, O\u2019Sullivan D, Soriano ER, Kavanaugh A (2022) GRAPPA treatment recommendations: 2021 update. J Rheumatol 49(6):52\u201354. https:\/\/doi.org\/10.3899\/jrheum.211331","journal-title":"J Rheumatol"},{"key":"8173_CR8","doi-asserted-by":"publisher","unstructured":"Alonso JCT et al (2023)\u00a0Expert recommendations for the use of apremilast in psoriatic arthritis. Reumatol Clin\u00a019(1):34\u201344. https:\/\/doi.org\/10.1016\/j.reuma.2022.01.002","DOI":"10.1016\/j.reuma.2022.01.002"},{"issue":"6","key":"8173_CR9","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the Rheumatic Diseases 83(6):706\u2013719. https:\/\/doi.org\/10.1136\/ard-2024-225531","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8173_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A et al (2024) Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 83(6):760\u2013774. https:\/\/doi.org\/10.1136\/ard-2024-225534","journal-title":"Ann Rheum Dis"},{"key":"8173_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/ptt.s303634","volume":"11","author":"M Milakovic","year":"2021","unstructured":"Milakovic M, Gooderham MJ (2021) Phosphodiesterase-4 inhibition in psoriasis. Psoriasis Targets Ther 11:21\u201329. https:\/\/doi.org\/10.2147\/ptt.s303634","journal-title":"Psoriasis Targets Ther"},{"issue":"12","key":"8173_CR12","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2018-213463","volume":"77","author":"B Michelsen","year":"2018","unstructured":"Michelsen B et al (Dec.2018) Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified disease activity index for psoriatic arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 77(12):1736\u20131741. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213463","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8173_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3899\/jrheum.100857","volume":"38","author":"A Cauli","year":"2011","unstructured":"Cauli A et al (2011) Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. Journal of Rheumatology 38(5):898\u2013903. https:\/\/doi.org\/10.3899\/jrheum.100857","journal-title":"J Rheumatol"},{"issue":"12","key":"8173_CR14","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3899\/jrheum.150595","volume":"42","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A (2015) Patient\u2019s global assessment as an outcome measure for psoriatic arthritis in clinical practice: surrogate for measuring low disease activity? J Rheumatol 42(12):2332\u20132338. https:\/\/doi.org\/10.3899\/jrheum.150595","journal-title":"J Rheumatol"},{"issue":"5","key":"8173_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/03009742.2022.2151109","volume":"52","author":"I Koskivirta","year":"2023","unstructured":"Koskivirta I et al (2023) Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland. Scand J Rheumatol 52(5):549\u2013555. https:\/\/doi.org\/10.1080\/03009742.2022.2151109","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"8173_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.reuma.2023.06.007","volume":"20","author":"J Gratac\u00f3s-Masmitja","year":"2024","unstructured":"Gratac\u00f3s-Masmitja J et al (2024) Real-world apremilast use in biologic-na\u00efve psoriatic arthritis patients. Data from Spanish clinical practice. Reumatol Clin 20(1):24\u201331. https:\/\/doi.org\/10.1016\/j.reuma.2023.06.007","journal-title":"Reumatol Clin"},{"issue":"2","key":"8173_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40744-024-00641-w","volume":"11","author":"V Chandran","year":"2024","unstructured":"Chandran V et al (2024) Use of apremilast to achieve psoriatic arthritis treatment goals and satisfaction at 1 year in the Canadian real-world APPRAISE study. Rheumatol Ther 11(2):443\u2013455. https:\/\/doi.org\/10.1007\/s40744-024-00641-w","journal-title":"Rheumatol Ther"},{"issue":"5","key":"8173_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","volume":"24","author":"PJ Mease","year":"2023","unstructured":"Mease PJ et al (2023) Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Beh\u00e7et\u2019s syndrome. Am J Clin Dermatol 24(5):809\u2013820. https:\/\/doi.org\/10.1007\/s40257-023-00783-7","journal-title":"Am J Clin Dermatol"},{"key":"8173_CR19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55773","author":"RF Alharthy","year":"2024","unstructured":"Alharthy RF, Alharthy JM, Bawazir RO, Katib RI, Alharthy FS (Mar.2024) The efficacy and safety of apremilast in the management of psoriatic arthritis: a systematic review and meta-analysis. Cureus. https:\/\/doi.org\/10.7759\/cureus.55773","journal-title":"Cureus"},{"issue":"6","key":"8173_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1517\/14740338.2015.1031743","volume":"14","author":"S Busa","year":"2015","unstructured":"Busa S, Kavanaugh A (2015) Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf 14(6):979\u2013985. https:\/\/doi.org\/10.1517\/14740338.2015.1031743","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"8173_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.31138\/mjr.301223.dpa","volume":"34","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE et al (2023) Disease profile and achievement of therapeutic goals in a modern, nationwide cohort of 923 patients with psoriatic arthritis. Mediterr J Rheumatol 34(4):418\u2013426. https:\/\/doi.org\/10.31138\/mjr.301223.dpa","journal-title":"Mediterr J Rheumatol"},{"key":"8173_CR22","doi-asserted-by":"publisher","unstructured":"Zhao SS, Hernandez G, Alam U (2025) Risk of psoriatic arthritis among patients receiving apremilast versus methotrexate for psoriasis.\u00a0J Am Dermatol.\u00a0https:\/\/doi.org\/10.1093\/rheumatol.","DOI":"10.1093\/rheumatol"},{"key":"8173_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030398","author":"R Gualtierotti","year":"2019","unstructured":"Gualtierotti R, De Lucia O (2019) Efficacy and metabolic effect on serum lipids of apremilast in psoriatic arthritis: a case report. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8030398","journal-title":"J Clin Med"},{"key":"8173_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11714","author":"A Kavanaugh","year":"2024","unstructured":"Kavanaugh A et al (2024) Association between achievement of clinical disease control and improvement in patient-reported outcomes and quality of life in patients with psoriatic arthritis in the phase 3 SELECT-PsA 1 and 2 randomized controlled trials. ACR Open Rheumatol. https:\/\/doi.org\/10.1002\/acr2.11714","journal-title":"ACR Open Rheumatol"},{"key":"8173_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459185","author":"N Barbarroja","year":"2024","unstructured":"Barbarroja N, L\u00f3pez-Medina C, Escudero-Contreras A, Arias-de la Rosa I (2024) Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of Apremilast. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1459185","journal-title":"Front Immunol"},{"issue":"6","key":"8173_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/1346-8138.15293","volume":"47","author":"S Mazzilli","year":"2020","unstructured":"Mazzilli S et al (2020) Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers. J Dermatol 47(6):578\u2013582. https:\/\/doi.org\/10.1111\/1346-8138.15293","journal-title":"J Dermatol"},{"key":"8173_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1407871","author":"T Fan","year":"2024","unstructured":"Fan T et al (2024) PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1407871","journal-title":"Front Pharmacol"},{"issue":"5","key":"8173_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/obr.12385","volume":"17","author":"C Wu","year":"2016","unstructured":"Wu C, Rajagopalan S (2016) Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders. Obes Rev 17(5):429\u2013441. https:\/\/doi.org\/10.1111\/obr.12385","journal-title":"Obes Rev"},{"issue":"5","key":"8173_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00296-022-05269-z","volume":"43","author":"PP Sfikakis","year":"2023","unstructured":"Sfikakis PP et al (2023) Apremilast for biologic-na\u00efve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study. Rheumatol Int 43(5):889\u2013902. https:\/\/doi.org\/10.1007\/s00296-022-05269-z","journal-title":"Rheumatol Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08173-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:46:15Z","timestamp":1790999175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08173-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8173"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08173-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the local Ethics Committees of the participating centers. Written informed consent was obtained from all patients prior to inclusion in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}